VRTX - Vertex Pharmaceuticals Inc
A biotechnology company that transformed cystic fibrosis treatment with its Trikafta franchise, and is now expanding into pain management and other genetic diseases.
Finlify Score
48.7 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$481.70
-0.34%
52W Range
$362.50 - $533.67
Market Cap
$115.0B
-0.3%Compared to previous day
2026 Q1 Revenue
$3.0B
-6.4%Changes from last reporting quarter
2026 Q1 EPS
$4.02
Diluted shares
Analyst Rating
40 analysts in latest ratings feed
RSI
47.0
40-70 moderate
2Y Range Position
70%
-9.7% from high / +32.9% from low
Beta
0.30
Relative to market benchmark
MACD
-1.74
MACD line 2.13 / signal line 3.88
Fundamental Trend
Growth 31.2Financial Health
Quality 73.4Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD48.7 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $3.0B-6.4% | $3.2B+3.7% | $3.1B+3.8% | $3.0B+7.0% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.1B-5.6% | $1.2B+1.7% | $1.2B+3.0% | $1.2B+82.7% |
| Net Income | $1.0B-13.4% | $1.2B+10.0% | $1.1B+4.8% | $1.0B+59.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's signal for VRTX is HOLD, with a Finlify Score of 49.4/100, suggesting a neutral stance. This appears to be influenced by strong accumulation balanced against lower relative strength and fundamental trend scores.
Technical
The asset's Relative Strength score of 24.8/100 indicates underperformance compared to peers, yet the Accumulation / Volume score is very high at 97.0/100, suggesting significant buying interest on volume. The RSI(14) of 46.3 appears neutral, and while the 20-day return was a modest -0.4%, the asset has seen an 11.1% return over the past 60 days.
Fundamentals
The Fundamental Trend score of 31.2/100 suggests some concerns regarding the direction of underlying business performance, though Financial Quality is robust at 73.4/100. Valuation metrics such as a P/E of 30.6x, P/B of 6.2x, and P/S of 10.1x appear elevated, potentially indicating a premium valuation. The low Beta of 0.3 suggests lower volatility compared to the broader market.
Macro Context
The macro environment, characterized by CPI YoY at 3.7% and 10Y Treasury Yield at 4.7%, suggests persistent inflation and higher interest rates. For VRTX, with its low beta of 0.3, this environment may indicate some resilience to broader market shifts, though higher rates could influence growth stock valuations.
Key Risks
- The Fundamental Trend score of 31.2/100 suggests potential concerns regarding the trajectory of the underlying business performance.
- Valuation multiples, including a P/E of 30.6x, P/B of 6.2x, and P/S of 10.1x, appear elevated, which may indicate a premium valuation.
- The upcoming earnings announcement on 2026-08-03 introduces event-specific volatility and uncertainty.